Comparing the Survival Outcomes of Radical Prostatectomy Versus Radiotherapy for Patients With De Novo Metastasis Prostate Cancer: A Population-Based Study

Xiaoxiao Guo,† Haoran Xia,† Xiaonan Su, Huiming Hou, Qiuzi Zhong*, and Jianye Wang*

Department of Urology, Beijing Hospital, National Center of Gerontology, Beijing, China, 2 Graduate School of Peking Union Medical College, Beijing, China, 3 Department of Radiotherapy, Beijing Hospital, National Center of Gerontology, Beijing, China, 4 Department of Urology, Zoucheng People’s Hospital, Zoucheng, China

Purpose: The efficacy of local treatments (LTs) in selected patients with metastatic prostate cancer (mPCa) had been demonstrated. However, the comparative effectiveness between LTs is unclear. Here, we compared the impact of radical prostatectomy (RP) and brachytherapy (RT) on the survival outcomes of mPCa patients.

Materials and Methods: mPCa patients who received RT or RP between 2004 and 2016 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Multivariable Cox proportional hazards analysis was used to evaluate the comparative risk of prostate cancer-specific mortality (CSM) and all-cause mortality (ACM) between LTs. A 1:1 propensity score matching (PSM) and adjusted standardized mortality ratio weighting (SMRW) were performed to balance the clinicopathological characteristics of the groups.

Results: Of 684 mPCa patients, 481 underwent RP and 203 received RT. After PSM, both groups included 148 cases, and RT resulted in comparable CSM versus RP [CSM: HR = 0.77, p = 0.325; ACM: HR = 0.73, p = 0.138], which was consistent with the SMRW model [CSM: HR = 0.83, p = 0.138; overall survival (OS): HR = 0.75, p = 0.132]. However, RP was associated with a lower CSM in the T1–2 subgroup (HR = 0.42, p = 0.048) and a lower ACM in the T1–2 (HR = 0.55, p = 0.031) and prostate-specific antigen (PSA) ≤20ng/ml (HR = 0.48, p = 0.022) subgroups. Besides, the results showed that the mortality risk was similar between the two groups in the T3–4, Gleason score (GS) >7, PSA >20 ng/ml, and all metastatic subgroups (all p > 0.100).
INTRODUCTION

Recently, the landscape of the management of metastatic prostate cancer (mPCa) is changing rapidly with the new generation of hormone therapies and other treatment options emerging and changing the paradigms that have persisted for decades (1). In this context, there is growing interest in whether local treatments (LTs) for the primary lesion could improve the survival outcomes of mPCa patients. This hypothesis is based on the seed and soil theory wherein, in animal models of cancer, the primary tumors metastasize not only by disseminating tumor cells into circulation but also by preparing the so-called pre-metastatic niche for metastasis implantation (2). The proliferation of metastasis at distant sites is stimulated and maintained by compounds secreted by primary cancer into circulation (3). Based on these concepts, LTs of the primary tumor could improve survival through inhibiting not just the initiation of distant disease but also the progression of the existing metastases.

Previous population-based studies had postulated a survival benefit for LTs versus non-local treatments (NLTs) in de novo mPCa patients (4-9). Furthermore, prospective randomized studies addressing the effect of LT by radiotherapy on the outcome of mPCa patients demonstrated its effect on selected individuals (10, 11). However, the comparative effectiveness between LTs, such as radical prostatectomy (RP) and brachytherapy (RT), is unclear. To this aim, we compared the impacts of RP and RT on the survival outcomes after adjustment for other clinicopathological characteristics in the most contemporary population-based cohort of mPCa patients.

Conclusions: RP could confer better survival outcomes than could RT in mPCa patients with favorable primary tumor features, but not in those with advanced primary tumor features. Moreover, the metastatic substage has limited impact on the comparative effectiveness between RP and RT. Further clinical trials are necessary to confirm the present results.

Keywords: metastatic prostate cancer, propensity score analysis, radical prostatectomy, radiotherapy, comparative effectiveness

PATIENTS AND METHODS

Study Population

We used the Surveillance, Epidemiology, and End Results (SEER) database to identify patients with mPCa from 2004 to 2016. The 18th SEER tumor registries encompass ~26% of the US population and collect information on cancer incidence, prevalence, survival, and mortality of cancer patients.

Firstly, we identified 590,960 patients diagnosed with prostate cancer (PCa). Individuals who underwent 1) RP with or without external beam radiation therapy or 2) RT with or without external beam radiation therapy were included. We excluded those who were without metastasis or had multiple primary tumors. Then, patients with incomplete clinicopathological data, such as T stage, prostate-specific antigen (PSA) value, and Gleason score (GS), were excluded. Those who received external beam radiation therapy alone were also excluded since there was lack of target site information distinguishing local from extraprostatic treatment. In addition, cases who received surgical treatments other than RP, e.g., transurethral resection of the prostate or cryotherapy, were removed. These selection criteria yielded 684 patients. The patient inclusion and exclusion diagrams are depicted in Figure 1.

Propensity Score Matching

Propensity score matching (PSM; a 1:1 matching algorithm with a specified caliper distance of 0.001 of the standard deviation of the logit) was conducted to yield similar patient characteristics between the radiotherapy (n = 148) and RP (n = 148) cohorts, imitate a randomized trial design, diminish residual and selection bias, and enhance precision. Age, year of diagnosis, the PSA level, clinical tumor stage, biopsy GS, and the American Joint Committee on Cancer (AJCC) M stage were adjusted using the logistic regression model to calculate the propensity scores. The standardized mean difference (SMD) and a propensity score density plot were used to evaluate the matching efficiency.

Statistical Analysis

A comparison of the baseline characteristics between the RT and RP groups was conducted for the unmatched and PSM cohorts using \( \chi^2 \) and Fisher’s exact tests. Metastatic stages (M-stages) are sub-stratified into the following: M1a, “non regional lymph nodes”; M1b, “bone(s)”; and M1c, “other site(s) with or without bone disease. Hazard ratios (HRs) with 95% confidence intervals (95%CIs) for all-cause mortality (ACM) and cancer-specific mortality (CSM) owing to RT versus RP were calculated using the multivariate Cox proportional hazards model, both in the unmatched and PSM cohorts, with age, PSA, race, biopsy Gleason score, clinical tumor stage, and metastatic substages serving as covariates. The standardized mortality ratio weighting (SMRW) model that makes the distribution of risk factors equal to that of the RT group was used to confirm the robustness of our outcomes. The overall survival (OS) and cancer-specific survival (CSS) of patients treated with RT or RP in the unmatched and PSM cohort were estimated using the Kaplan–Meier survival curve. Subsequently, subgroup analyses on the basis of clinical tumor stage (T_{1-2} and T_{3-4}), metastatic substage (M_{1a-1b} and M_{1c}), biopsy GS (\leq 7 and >7), and PSA levels (\leq 20 and <20 ng/ml) were conducted. All tests were two sided, with statistical significance set at \( p < 0.05 \). Analyses were
performed with the statistical package for R (version 3.6.1; the R Foundation for Statistical Computing, Vienna, Austria).

**RESULTS**

As Table 1 shows, prior to PSM, the RT and RP groups included 203 and 481 patients, respectively. Patients in the RT group were older (68 years) relative to those in the RP group (63 years). The rate for clinical tumor stage T2 or lower was higher in the RT group (83.2%) than that in the RP group (34.9%). The rate for Gleason score $\geq 7$ was higher in the RP group (90.9%). Patients who underwent RP had a larger proportion of M1a disease than those treated with RT (17.3% vs. 8.9%). Besides, those in the RP group have been generally treated more recently ($p < 0.001$) compared with those in the RT group. The two groups were well balanced after PSM, given that no significant differences were observed for all key variables. The propensity score distributions of the RT and RP groups in the unmatched cohort was highly heterogeneous (Figure 2A) and it in the PSM and SMRW cohorts were highly consistent (Figures 2B, C). All of the SMD values of the key variables in the PSM and SMRW cohorts were <10% and were far less than those in the unmatched cohort (Figure 2D).

In the unmatched cohort, the Cox proportional hazards model revealed that there was no significant difference between the CSM or the ACM of the two groups (CSM: HR = 0.86, 95% CI = 0.57–1.27, $p = 0.444$; ACM: HR = 0.78, 95%CI = 0.56–1.09, $p = 0.148$). Consistently, in the PSM cohort, there was no significant difference regarding CSM or ACM risk between the two groups (CSM: HR = 0.77, 95%CI = 0.46–1.30, $p = 0.325$;

---

**FIGURE 1** | Exclusion criteria used to derive the final study cohort from the SEER database from 2004 to 2016. RP, radical prostatectomy with or without external beam radiation therapy; RT, brachytherapy with or without external beam radiation therapy; PSA, prostate-specific antigen; GS, Gleason score.
ACM: HR = 0.73, 95%CI = 0.48–111, p = 0.138), which was supported by the outcomes in the adjusted SMRW model as well (CSM: HR = 0.83, 95%CI = 0.53–1.32, p = 0.435; ACM: HR = 0.75, 95%CI = 0.52–1.09, p = 0.123). The above results are summarized in Table 2. The Kaplan–Meier survival curves showed that the 10-year survival rates of RP versus RT before PSM were 70.5% vs. 56.7% for CSS and 55.8% vs. 37.0% for OS. After PSM, the 10 year CSS rates of RT versus RT were 73.8% vs. 66.7% and the 10-year OS rates were 60.8% vs. 45.6.0% (Figure 3).

In the subgroup analysis, RP was associated with a lower CSM in the T1–2 subgroup (HR = 0.42, 95%CI = 0.17–0.99, p = 0.048).

**FIGURE 2** | Propensity score distribution in the unmatched cohort (A), propensity score matching (PSM) cohort (B), and the standardized mortality ratio weighting (SMRW) cohort (C) and the standardized mean difference (SMD) of the key variables in the unmatched, PSM, and SMRW cohorts (D). RT, brachytherapy with or without external beam radiation therapy; RP, radical prostatectomy with or without external beam radiation therapy; PSM, propensity score matching; PSA, prostate-specific antigen.

**TABLE 1** | Baseline demographic and clinicopathologic characteristics sorted by local treatments before and after PSM.

|              | Before PSM | p-value | After PSM | p-value |
|--------------|------------|---------|-----------|---------|
| Age (year)²  | 68.0 [59.5–73.0] | <0.001 | 65.0 [56.0–72.0] | 0.013 |
| PSA (ng/ml)² | 15.6 [8.6–72.0] | <0.001 | 15.0 [5.8–38.7] | 0.888 |
| Race³        | 0.014      |         | 0.655     |         |
| Caucasian    | 148 (72.9) |         | 110 (74.3) | 0.548   |
| African      | 44 (21.7)  |         | 24 (16.2)  | 0.107   |
| Other        | 11 (5.4)   |         | 14 (9.5)   | 0.107   |
| Year of diagnosis³ | <0.001 |         | <0.001     |         |
| 2004–2007    | 80 (39.4)  |         | 58 (39.2)  | 0.851   |
| 2008–2011    | 63 (31.0)  |         | 38 (25.7)  | 0.928   |
| 2012–2016    | 60 (29.6)  |         | 52 (35.1)  | 0.928   |
| Clinical T stage³ | <0.001 |         | <0.001     |         |
| T1           | 102 (50.2) |         | 18 (12.2)  | 0.014   |
| T2           | 67 (33.0)  |         | 72 (48.6)  | 0.928   |
| T3           | 27 (13.3)  |         | 48 (32.4)  | 0.928   |
| T4           | 7 (3.4)    |         | 10 (6.8)   | 0.928   |
| Gleason score³ | 0.014     |         | 0.014      |         |
| ≤6           | 33 (16.3)  |         | 18 (12.2)  | 0.013   |
| 7            | 55 (27.1)  |         | 40 (27.0)  | 0.013   |
| ≥8           | 115 (56.7) |         | 90 (60.8)  | 0.013   |
| AJCC M stage³ | 0.009     |         |            | 0.013   |
| M1a          | 18 (8.9)   |         | 24 (16.2)  | 0.013   |
| M1b          | 145 (71.4) |         | 94 (63.5)  | 0.013   |
| M1c          | 40 (19.7)  |         | 30 (18.9)  | 0.013   |
| Follow-up (months)³ | 45.0 [17.5–88.5] | 0.01 | 56.5 [18.0–110.0] | 0.013 |

**PSM, propensity score matching; RP, radical prostatectomy with or without external beam radiation therapy; RT, brachytherapy with or without external beam radiation therapy; PSA, prostate-specific antigen.

²Data are presented as median (interquartile range).

³Data are presented as n (%).
In addition, the CSM differences between RT and RP were close to being statistically significant in the GS \(\leq 7\) and PSA \(\leq 20\) ng/ml subgroups (HR = 0.30, 95%CI = 0.08–1.05, \(p = 0.058\); HR = 0.41, 95%CI = 0.16–1.01, \(p = 0.053\), respectively). However, the analysis showed that the CSM rates were similar between the two groups in the T3–4, GS >7, PSA >20 ng/ml, and all M-stage subgroups (Figure 4). Regarding the ACM, the RP group had better performance in the T1–2 and PSA \(\leq 20\) ng/ml subgroups (T1–2: HR = 0.55, 95%CI = 0.32–0.95, \(p = 0.031\); PSA \(\leq 20\) ng/ml: HR = 0.48, 95%CI = 0.36–0.90, \(p = 0.022\)). In patients with GS \(\leq 7\) disease, the RP group had a tendency of lower ACM (HR = 0.079, 95%CI = 0.47–1.33, \(p = 0.057\)). Furthermore, RT and RP performed equivalently in patients in the T3–4, GS >7, PSA >20 ng/ml, and all M-stage subgroups.

**TABLE 2 | Effect of RT and RP on the survival outcomes.**

| HR            | 95%CI          | \(p\)-value |
|---------------|----------------|-------------|
| Cancer-specific mortality |                |             |
| Adjusted non-matched cohort | 0.86         | 0.58–1.27   | 0.444       |
| Adjusted PSM cohort | 0.77         | 0.46–1.30   | 0.325       |
| Adjusted SMRW cohort | 0.83         | 0.53–1.32   | 0.435       |
| Adjusted non-matched cohort | 0.78         | 0.56–1.09   | 0.148       |
| Adjusted PSM cohort | 0.73         | 0.48–1.11   | 0.138       |
| Adjusted SMRW cohort | 0.75         | 0.52–1.09   | 0.132       |
| All-cause mortality |                |             |

RP: radical prostatectomy with or without external beam radiation therapy; RT, brachytherapy with or without external beam radiation therapy; HR, hazard ratio; CI, confidence interval; PSM, propensity score matching; SMRW, standardized mortality ratio weighting.

**DISCUSSION**

So far, retrospective data from a few studies had demonstrated a survival benefit or reduction in locoregional complication by the addition of LT to androgen deprivation therapy (ADT) in men with *de novo* mPCa (6, 9, 12–16). Local treatment of a primary tumor might prove beneficial through altering the natural course of the disease by slowing down the progression of metastasis, as others have described that the untreated primary PCa may act as a potential source of tumor spread and metastasis (17, 18). Moreover, in patients with locally advanced or nodal positive PCa, it may also improve the response to ADT (19, 20). Furthermore, the improved local tumor control could thereby decrease the need for subsequent palliative therapies, such as transurethral resection or urinary diversion. However, contemporary data are lacking to recommend one alternative local therapy over another. In the present study, we compared the survival outcomes between RT and RP for mPCa patients using a method with rigid case matching.

In our analysis, for the total cohort, there were no statistical CSS or OS differences between the RP and RT groups. The results after PSM and SMRW analysis confirmed the comparable survival outcomes of the two treatments. However, these results were different from an earlier database-based study. Leyh-Bannurah et al. identified 313 patients who received radical prostatectomy and 161 patients who received radiotherapy in the SEER database (4). They also performed PSM for the two treatment groups. The results suggested that RP was associated with a lower CSM than was RT (HR = 0.59, \(p = 0.048\)). A potential reason for the different findings between our study and that of Leyh-Bannurah et al. is that, in the latter cohort, patients with favorable primary tumor features, such as T1–2 or GS \(\leq 7\), represented a higher proportion of all cases. In addition, RP had better performance in mPCa patients with favorable primary tumor features, which would be discussed later. Moreover, in another retrospective study, Satkunasivam et al. identified 47, 88, and 107 patients who underwent RP, intensity-modulated radiation therapy (IMRT), and conformal radiation therapy (CRT), respectively, from the SEER-Medicare database to assess survival after RP, IMRT, or CRT vs. NLTs for mPCa. After PSM, they found that IMRT (62%, \(p < 0.001\)) and RP (52%, \(p = 0.01\)) lowered the CSM, whereas CRT did not (\(p = 0.3\)), when compared to NLTs (4). These results suggested that various external radiotherapy techniques may be another reason for the differences in the conclusions between studies. However, the specific radiotherapy technique was unavailable in SEER; therefore, we cannot conduct further analysis.

The subgroup analysis showed that RP confers a better survival benefit than does RT in patients with cT1–2 disease. In addition, RP showed a tendency of more effectiveness in the Gleason \(\leq 7\) and PSA \(\leq 20\) ng/ml substage. A survival benefit, however, was not observed in patients with advanced primary tumor. One possible reason accounting for the similar outcomes between RP and RT in patients with advanced clinicopathological features is that, LTs, such as RP and RT, have little effect on survival for this population. As the results of a previously mentioned study reported (4), the effect of LTs on survival had an interaction with the risk criteria (GS \(\geq 8\), cT4, and M1b–c substage); that is, RP and RT are less effective in patients with two or more risk criteria than in those with one or fewer risk criteria. Moreover, in another SEER-based study evaluating LTs for patients with mPCa, Pompe et al. found a significant interaction between PSA and treatment type in M1b patients. LTs conferred a survival benefit when PSA was \(< 60\) ng/ml, with maximum benefit when PSA was \(< 40\) ng/ml. However, no survival benefit existed for M1b patients above the 60-ng/ml PSA threshold (21). Furthermore, the results of the HORRAD trial also suggested the dissatisfactory efficacy of LTs in mPCa patients with advanced primary tumor characteristics. It randomly recruited 432 patients with PSA >20 ng/ml and...
primary bone mPCa between 2004 and 2014. The study demonstrated that the protective association of RP with CSM was not recorded in these individuals (11). These results noted that comparing the effectiveness of LTs must be conditional upon LTs being better than NLTs. If not, it is meaningless to compare the efficacy between LTs.

Our results suggested that M-substages has an insignificant influence on the comparative CSM risk of RP vs. RT ($p = 0.192$ in $M_{1a-b}$ substages; $p = 0.470$ in $M_{1c}$ substage). A handle of studies had evaluated the effect of M-substage on the efficacy of LTs. For example, Pompe et al. evaluated the impact of baseline PSA and metastatic substages on the survival benefit of LTs vs. NLTs for

---

**FIGURE 3** | CSS and OS of the RP and RT groups before PSM (A, B) and after PSM (C, D). CSS, prostate cancer-specific survival; OS, overall survival; RP, radical prostatectomy with or without external beam radiation therapy; RT, brachytherapy with or without external beam radiation therapy.
mPCa based on SEER and found that a survival benefit existed for patients with M1b PCa, but not for those with M1c PCa (21). Furthermore, the follow-up of the STAMPEDE trial suggested that the RT for mPCa did not confer an OS advantage for the complete study population, but did for the low metastatic burden subgroup, which was defined using CHAARTED (Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) (10). However, none of these studies was tailored to determine the effect of M-substage on the comparative effectiveness of RT and RP. Our results indicated that the efficacy of the different LTs is largely determined by the characteristics of the primary tumor rather than the M-substage.

Our study is not devoid of limitations. Firstly, site-specific external beam radiation therapy (EBRT) codes are unavailable in the SEER database and only RT codes were analyzed. Secondly, the SEER database does not identify additional therapies such as ADT, chemotherapy, or other systemic agents as they represent the gold standard therapy for men with mPCa (1). Thirdly, the SEER database does not provide complete information regarding the exact metastatic burden, such as the number of metastatic diseases, except for the M-substages that were included in the analyses. Finally, similar to all previous studies, this study is retrospective in nature. Besides, the SEER database does not provide information on comorbidities and performance status, which may be used for patient selection.

CONCLUSIONS

Our study provides evidence that, for mPCa, RP could confer better survival outcomes than could RT in those with favorable local stage, Gleason score, or PSA value. However, in patients with advanced local tumor characteristics, RP and RT provide similar survival outcomes. Furthermore, the metastatic substage has a limited impact on the comparative effectiveness between RP and RT. It is important to consider the study limitations until ongoing clinical trials confirm the proposed benefits.

DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study. This data can be found here: https://seer.cancer.gov/data/.

ETHICS STATEMENT

The data in this study were derived from the SEER database. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The SEER Program collects data from population-based cancer registries with anonymous information. It is a publicly available database; thus, no ethical approval is required.

AUTHOR CONTRIBUTIONS

XG and HX performed formal analysis and wrote the original draft. XS and HH helped with the methodology. JW conceptualized the study. QZ contributed to the conceptualization, funding acquisition, resources, and supervision. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by the Beijing Hospital Clinical Research 121 Project (BJ-2020-171).
REFERENCES

1. Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. *Eur Urol* (2021) 79:263–82.

2. Kaplan RN, Ribis RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-Positive Haematopoietic Bone Marrow Progenitors Initiate the Pre-Metastatic Niche. *Nature* (2005) 7069:820–7. doi: 10.1038/nature01186

3. McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saeltzer MP, Ince TA, et al. Systemic Endocrine Instigation of Indolent Tumor Growth Requires Osteopontin. *Cell* (2008) 6:994–1005. doi: 10.1016/j.cell.2008.04.045

4. Leyh-Bannurah SR, Gazdovich S, Budäus L, Zaffuto E, Briganti A, Abdollah F, et al. Local Therapy Improves Survival in Metastatic Prostate Cancer. *Eur Urol* (2017) 1:118–24. doi: 10.1016/eururo.2017.03.020

5. Ruhstoven CG, Jones BL, Flagg TW, Crawford ED, Koshy M, Sher DJ, et al. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. *J Clin Oncol* (2016) 24:2835–42. doi: 10.1200/jco.2016.67.4788

6. Culp SH, Schellhammer PF, Williams MB. Might Men Diagnosed With Metastatic Prostate Cancer Benefit From Definitive Treatment of the Primary Tumor? A SEER-Based Study. *Eur Urol* (2014) 6:1058–66. doi: 10.1016/j.eururo.2013.11.012

7. Gratzke C, Engel J, Stief CG. Role of Radical Prostatectomy in Metastatic Prostate Cancer: Data From the Munich Cancer Registry. *Eur Urol* (2014) 6:602–3. doi: 10.1016/eururo.2014.04.009

8. Parkh RR, Byun J, Goyal S, Kim IY. Local Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate Cancer. *Prostate* (2017) 6:599–72. doi: 10.1002/pros.32394

9. Lüppenbergh B, Dalela D, Karabon P, Sood A, Sammon JD, Meyer CP, et al. The Impact of Local Treatment on Overall Survival in Patients With Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis. *Eur Urol* (2017) 1:14–9. doi: 10.1016/eurol.2016.04.031

10. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Might Males Diagnosed With Nonmetastatic Prostate Cancer Benefit From Local Treatment? A SEER-Based Study. *Eur Urol* (2017) 1:118–24. doi: 10.1016/eururo.2017.03.020

11. Petroianu G, Bergh A, Pahlman L, Amin MB, Hammerstedt RH, Kuczykowski M, et al. Robotically Assisted Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer. *Eur Urol* (2018) 6:693–6. doi: 10.1016/eururo.2018.07.006

12. Rusthoven CG, Jones BL, Flagg TW, Crawford ED, Koshy M, Sher DJ, et al. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. *J Clin Oncol* (2016) 24:2835–42. doi: 10.1200/jco.2016.67.4788

13. Culp SH, Schellhammer PF, Williams MB. Might Men Diagnosed With Metastatic Prostate Cancer Benefit From Definitive Treatment of the Primary Tumor? A SEER-Based Study. *Eur Urol* (2014) 6:1058–66. doi: 10.1016/j.eururo.2013.11.012

14. Herrmann F, Pfister D, Torres D. Cytoreductive Radical Prostatectomy in Patients With Prostate Cancer and Low Volume Skeletal Metastases: Results of a feasibility and Case-Control Study. *J Urol* (2015) 3:832–8. doi: 10.1016/j.juro.2014.09.089

15. Preiss F, Mazzone E, Nazzani S, Bandini M, Tian Z, Marchioni M, et al. Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer. *Eur Urol* (2018) 6:693–6. doi: 10.1016/eururo.2018.07.006

16. Preiss F, Nazzani S, Mazzone E, Marchioni M, Bandini M, Tian Z, et al. Comparison of Open Versus Robotically Assisted Cytoreductive Radical Prostatectomy for Metastatic Prostate Cancer. *Clin Genitourin Cancer* (2019) 5:939–45. doi: 10.1016/j.clgc.2019.05.022

17. Kaplan RN, Rafi S, Lyden D. Preparing the “Soil”: The Premetastatic Niche. *Cancer Res* (2006) 23:11089–93. doi: 10.1158/0008-5472.Can-06-2407

18. Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, et al. Tracking the Clonal Origin of Lethal Prostate Cancer. *J Clin Invest* (2013) 11:4918–22. doi: 10.1172/jci70354

19. Verhaeg BE, Schröder FH, Collette L, Bangma CH. Does Local Treatment of the Prostate in Advanced and/or Lymph Node Metastatic Disease Improve Efficacy of Androgen-Degradation Therapy? A Systematic Review. *Eur Urol* (2010) 2:261–9. doi: 10.1016/j.eururo.2010.05.027

20. Niklas C, Saar M, Nini A, Linxweiler J, Siemer S, Junker K, Junker k, et al. Can Local Treatment Prolong the Sensitivity of Metastatic Prostate Cancer to Androgen Degradation or Even Prevent Castration Resistance? *World J Urol* (2021) 9:3231–7. doi: 10.1007/s00345-020-05368-3

21. Pompe RS, Tilki D, Preisser F, Leyh-Bannurrah SR, Bandini M, Marchioni M, et al. Survival Benefit of Local Versus No Local Treatment for Metastatic Prostate Cancer—Impact of Baseline PSA and Metastatic Substages. *Prostate* (2018) 10:753–7. doi: 10.1002/pros.23519

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Guo, Xia, Su, Hou, Zhong and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.